Mechanism
Growth hormone (GH) is secreted by pituitary somatotrophs under dual control of stimulatory GHRH and inhibitory somatostatin — GHRPs and GHRH analogues act on distinct components of this axis to amplify pulsatile GH release.
Growth hormone is a 191-amino acid peptide hormone synthesised and secreted by somatotroph cells in the anterior pituitary. Its effects span anabolism, lipolysis, skeletal growth, immune modulation, and metabolic regulation — the majority of which are mediated indirectly through downstream induction of insulin-like growth factor 1 (IGF-1). GH secretion is inherently pulsatile: healthy adults produce 6–8 discrete GH pulses per day, with the largest pulse occurring during slow-wave (deep) sleep. Between pulses, circulating GH concentrations fall to near-undetectable levels. This pulsatile architecture is not incidental — it is essential to normal GH receptor biology. Continuous GH exposure, as produced by exogenous recombinant GH injection, desensitises the GH receptor and generates a metabolic profile that differs meaningfully from physiological pulsatile secretion, with greater propensity for insulin resistance and a qualitatively different anabolic signal. GH secretion declines progressively with age, a process termed the somatopause: peak GH output at puberty declines by roughly 14% per decade through adulthood, contributing to age-related changes in body composition, bone density, sleep architecture, and recovery capacity.
Peptide-based GH axis stimulation is investigated as a more physiologically faithful approach to restoring GH pulsatility than exogenous GH replacement. Rather than bypassing the hypothalamic-pituitary regulatory axis, growth hormone-releasing peptides (GHRPs) and GHRH analogues act upstream — stimulating the pituitary's own GH synthesis and secretion within the bounds of existing negative feedback mechanisms. This preserves the pulsatile character of GH release and keeps IGF-1 and cortisol within the regulatory context of the axis. The downstream effects of GH — protein synthesis, lipolysis, collagen deposition, chondrocyte proliferation, bone mineralisation, and hepatic glucose modulation — are largely shared whether GH originates endogenously or via secretagogue stimulation, making this axis a central target in research on aging, body composition, and tissue repair.
GH secretion is governed by two opposing hypothalamic inputs that converge on the pituitary somatotroph. The first is growth hormone-releasing hormone (GHRH), a 44-amino acid peptide produced by arcuate nucleus neurons that project axons to the median eminence and release GHRH into the hypothalamo-hypophyseal portal circulation. GHRH binds the GHRH receptor (GHRHR), a class B G protein-coupled receptor expressed on somatotrophs, and activates the Gs-cAMP-PKA signalling cascade. This drives phosphorylation of CREB, upregulates GH gene transcription, increases somatotroph intracellular calcium, and triggers exocytosis of GH-containing secretory vesicles. The second input is somatostatin (SST), also designated somatotropin-release inhibiting factor (SRIF), a 14- or 28-amino acid peptide produced by periventricular hypothalamic neurons. Somatostatin binds SSTR receptors (subtypes SSTR1–5) on somatotrophs, coupling through Gi to reduce cAMP production and suppress GH release. The rhythmic alternation between GHRH-dominant and somatostatin-dominant states — driven by the opposing oscillatory activity of these two hypothalamic neuron populations — generates the pulsatile GH secretion pattern observed in vivo. GH pulse amplitude is set largely by GHRH drive; GH pulse frequency is gated by somatostatin withdrawal.
GHRPs engage an entirely distinct receptor — GHS-R1a, the growth hormone secretagogue receptor, which is also the receptor for ghrelin, the endogenous 28-amino acid acylated peptide secreted primarily by the gastric fundus. GHS-R1a is a class A GPCR that couples through Gq rather than Gs. Gq activation drives phospholipase C (PLC) → inositol trisphosphate (IP3) → endoplasmic reticulum calcium release, generating a rapid intracellular calcium transient that potently triggers GH vesicle exocytosis. This calcium-mediated mechanism operates independently of the cAMP pathway engaged by GHRH, which is the molecular basis for their pharmacological synergy. When a GHRH analogue and a GHRP are co-administered, the cAMP and calcium signals summate at the level of the somatotroph, producing a GH pulse substantially larger than either compound alone — typically 2–4 fold larger in controlled studies. This is the mechanistic rationale for combination protocols such as CJC-1295 plus Ipamorelin. An additional pharmacological distinction: GHRP / GHS-R1a activation can partially overcome somatostatin-mediated inhibition, as GHS-R1a–Gq signalling can counteract some of the Gi-mediated cAMP suppression produced by somatostatin. GHRH analogues, by contrast, are more sensitive to somatostatin gating — their efficacy is substantially reduced when hypothalamic somatostatin tone is high.
Following pituitary release, circulating GH acts on peripheral tissues via the GH receptor (GHR), a class I cytokine receptor expressed broadly — most importantly in the liver, skeletal muscle, adipose tissue, and bone. GHR activation triggers trans-autophosphorylation of receptor-associated JAK2 (Janus kinase 2), which in turn phosphorylates STAT5 (signal transducer and activator of transcription 5). Phosphorylated STAT5 dimerises, translocates to the nucleus, and drives transcription of IGF-1 and other GH-responsive genes. Hepatic IGF-1 is secreted into the circulation and accounts for the majority of systemic IGF-1 — though local (paracrine/autocrine) IGF-1 production occurs in muscle, bone, and other tissues in response to GH. IGF-1 mediates most of the anabolic effects attributed to GH: it activates the PI3K-Akt-mTOR pathway in skeletal muscle to stimulate protein synthesis and suppress proteolysis; it drives chondrocyte proliferation and collagen matrix synthesis in cartilage; it promotes osteoblast activity and bone mineralisation; and it stimulates fibroblast activity relevant to collagen deposition and wound repair. IGF-1 also closes the regulatory loop: elevated IGF-1 feeds back to the hypothalamus to suppress GHRH secretion and increase somatostatin tone, and acts directly on pituitary somatotrophs to reduce GH output — the canonical GH-IGF-1 negative feedback axis.
The temporal pattern of GH exposure — pulsatile versus continuous — produces qualitatively different physiological responses, even at equivalent mean GH concentrations. Pulsatile GH delivery is associated with predominantly anabolic effects: robust JAK2-STAT5 signalling with interval recovery, IGF-1 synthesis, and preservation of GH receptor density. Continuous GH exposure leads to GHR downregulation, receptor desensitisation, and a shift toward pronounced lipolysis and insulin resistance with attenuated anabolic signalling. This distinction is directly relevant to research design: secretagogue-based protocols (GHRPs, GHRH analogues, or their combination) stimulate endogenous, pulsatile GH release rather than imposing a continuous pharmacokinetic profile. The largest physiological GH pulse occurs during the first episode of slow-wave sleep, driven by a nocturnal surge in GHRH and a concurrent withdrawal of somatostatin. For this reason, research protocols investigating GH secretagogues frequently employ evening or pre-sleep dosing, with the rationale of amplifying the nocturnal GH peak rather than creating a daytime pulse that competes with normal somatostatin tone.
| Compound | Pathway | Primary Action | Profile |
|---|---|---|---|
| Ipamorelin | Ghrelin receptor (GHS-R1a) | Selective GH pulse stimulation; minimal cortisol/prolactin | High GH selectivity; well-tolerated in research |
| CJC-1295 | GHRH receptor | Long-acting GH pulse amplitude enhancement | Extended half-life via DAC or native sequence; synergistic with GHRPs |
| Tesamorelin | GHRH receptor | Visceral fat reduction via GH axis; FDA-approved | Stabilised GHRH analogue; established clinical efficacy |
The molecular characterisation of GHRH in 1982 by Vale, Rivier, and colleagues opened the modern era of GH axis pharmacology. Synthetic GHRPs were developed through the 1980s in parallel work by Bowers and colleagues, who identified the ghrelin receptor as a distinct GH-stimulatory target before its endogenous ligand was known. GHS-R1a was cloned in 1996 by Howard and colleagues; ghrelin itself — its endogenous ligand — was isolated and characterised in 1999 by Kojima and Kangawa. The first-generation GHRH analogue Sermorelin (GHRH 1–29 NH2) advanced through phase 1–3 clinical trials in the 1990s and early 2000s for GH deficiency and adult somatopause. Tesamorelin, a trans-3-hexenoic acid-stabilised GHRH analogue, achieved FDA approval in 2010 for HIV-associated lipodystrophy — the first and, to date, only approved GHRH analogue — providing a clinical proof-of-concept for GH axis peptide pharmacology. Ongoing preclinical and clinical research continues to investigate GHS-R1a and GHRHR agonists across a range of metabolic and aging-related indications.
Current research in this area spans several converging domains. Age-related somatopause and the feasibility of restoring physiological GH pulsatility in older adults — without the adverse effects associated with supraphysiological exogenous GH — remains an active area of investigation. Body composition studies in GH-deficient adults have examined both GHRH analogues and GHRPs for effects on lean mass, visceral adiposity, and bone density. HIV lipodystrophy, characterised by visceral fat accumulation and metabolic dysregulation, is an established clinical indication for tesamorelin with multiple published trials. Sleep quality research has explored whether GH secretagogues, by amplifying the nocturnal GH pulse, can enhance slow-wave sleep architecture and GH-dependent tissue repair processes. A broader research question — whether peptide-based GH secretagogue protocols can replicate the anabolic, lipolytic, and repair-promoting benefits of direct GH replacement at a fraction of the cost and with improved safety profiles through preserved feedback regulation — remains a central driver of interest in this class.